[HTML][HTML] Molecular targeted therapy for anticancer treatment
HY Min, HY Lee - Experimental & molecular medicine, 2022 - nature.com
Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …
[HTML][HTML] The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
The RAS oncogene is both the most frequently mutated oncogene in human cancer and the
first confirmed human oncogene to be discovered in 1982. After decades of research, in …
first confirmed human oncogene to be discovered in 1982. After decades of research, in …
[HTML][HTML] The role of EREG/EGFR pathway in tumor progression
WL Cheng, PH Feng, KY Lee, KY Chen… - International journal of …, 2021 - mdpi.com
Aberrant activation of the epidermal growth factor receptor (EGFR/ERBB1) by erythroblastic
leukemia viral oncogene homolog (ERBB) ligands contributes to various tumor …
leukemia viral oncogene homolog (ERBB) ligands contributes to various tumor …
[HTML][HTML] Drug resistance in colorectal cancer: from mechanism to clinic
Simple Summary Chemotherapy, radiotherapy and molecularly targeted therapy could
improve the prognosis of colorectal cancer (CRC) patients. Recently, immunotherapy …
improve the prognosis of colorectal cancer (CRC) patients. Recently, immunotherapy …
Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: approaching to a new era of cancer chemotherapy
Although chemotherapy is a first option in treatment of cancer patients, drug resistance has
led to its failure, requiring strategies to overcome it. Cancer cells are capable of switching …
led to its failure, requiring strategies to overcome it. Cancer cells are capable of switching …
[HTML][HTML] EGFR-Based targeted therapy for colorectal cancer—Promises and challenges
B Janani, M Vijayakumar, K Priya, JH Kim… - Vaccines, 2022 - mdpi.com
Colorectal carcinoma (CRC) is the most lethal and common form of cancer in the world. It
was responsible for almost 881,000 cancer deaths in 2018. Approximately 25% of cases are …
was responsible for almost 881,000 cancer deaths in 2018. Approximately 25% of cases are …
Proteomics of post-translational modifications in colorectal cancer: Discovery of new biomarkers
G Zhu, L Jin, W Sun, S Wang, N Liu - … et Biophysica Acta (BBA)-Reviews on …, 2022 - Elsevier
Colorectal cancer (CRC) is one of the costliest health problems and ranks second in cancer-
related mortality in developed countries. With the aid of proteomics, many protein …
related mortality in developed countries. With the aid of proteomics, many protein …
[HTML][HTML] Nanotechnology for colorectal cancer detection and treatment
Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause
of cancer-related mortality in the United States. Across the globe, people in the age group …
of cancer-related mortality in the United States. Across the globe, people in the age group …
[HTML][HTML] Interleukin-8 in colorectal cancer: a systematic review and meta-analysis of its potential role as a prognostic biomarker
C Bazzichetto, M Milella, I Zampiva, F Simionato… - Biomedicines, 2022 - mdpi.com
Among soluble actors that have emerged as druggable factors, the chemokine interleukin-8
(IL-8) has emerged as a possible determinant of response to immunotherapy and targeted …
(IL-8) has emerged as a possible determinant of response to immunotherapy and targeted …
The pathological role of CXC chemokine receptor type 4 (CXCR4) in colorectal cancer (CRC) progression; special focus on molecular mechanisms and possible …
Colorectal cancer (CRC) is comprised of transformed cells and non-malignant cells
including cancer-associated fibroblasts (CAF), endothelial vasculature cells, and tumor …
including cancer-associated fibroblasts (CAF), endothelial vasculature cells, and tumor …